Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Cetuximab + Cisplatin + Vinorelbine
Indication/Tumor Type lung non-small cell carcinoma
Response Type no benefit


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung non-small cell carcinoma no benefit Cetuximab + Cisplatin + Vinorelbine Phase III Actionable In a Phase III clinical trial, the addition of Erbitux (cetuximab) to Platinol (cisplatin) and Navelbine (vinorelbine) chemotherapy resulted in improved median overall survival of 11.3 months, compared to 10.1 months with chemotherapy alone, and an overall response rate of 36% (203/557) vs. 29% (166/568) with chemotherapy alone in patients with non-small cell lung cancer (PMID: 19410716). 19410716
PubMed Id Reference Title Details
(19410716) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Full reference...